Affluent Medical S.A.
AFME.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.11 | 0.10 | -1.67 | -1.83 |
| FCF Yield | -21.60% | -22.82% | -35.38% | -12.00% |
| EV / EBITDA | -5.07 | -5.18 | -3.55 | -10.48 |
| Quality | ||||
| ROIC | -27.10% | -23.91% | -21.98% | -19.63% |
| Gross Margin | -225.16% | -98.04% | -82.45% | -88.90% |
| Cash Conversion Ratio | 0.77 | 0.77 | 0.73 | 0.83 |
| Growth | ||||
| Revenue 3-Year CAGR | 45.42% | -5.51% | 17.57% | 0.51% |
| Free Cash Flow Growth | 6.27% | -9.01% | 11.58% | -37.42% |
| Safety | ||||
| Net Debt / EBITDA | -1.12 | -1.16 | -1.15 | -0.77 |
| Interest Coverage | -64.83 | -33.25 | -11.00 | -4.33 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 176.77 | 506.29 | 652.24 | 488.97 |